comparemela.com

Latest Breaking News On - நாஸ்டாக் முதல் வடக்கு வளர்ச்சி - Page 25 : comparemela.com

Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market

Modus Therapeutics Appoints Sedermera Fondkommission as Financial Advisor to Support Planned Listing on Nasdaq First North Growth Market - Listing to fund the clinical development of sevuparin for sepsis/septic shock - No pharmaceutical products are currently available that are specifically meant to treat patients with sepsis/septic shock News provided by Share this article STOCKHOLM, March 15, 2021 /PRNewswire/ Modus Therapeutics Holding AB, a company developing innovative treatments for patients with high unmet medical needs, announces that it has appointed Sedermera Fondkommission as financial adviser to support its planned listing on Nasdaq First North Growth Market. The engagement of Sedermera Fondkommission follows the appointment of Claes Lindblad at Modus Therapeutics as its new Chief Financial Officer.

Minesto and Schneider Electric join forces to commercialize marine energy

Minesto of Sweden pairs with Schneider Electric on tidal energy scale-up

InDex Pharmaceuticals updates shareholders list

InDex Pharmaceuticals updates shareholders list News provided by Share this article STOCKHOLM, March 12, 2021 /PRNewswire/ InDex Pharmaceuticals Holding AB (publ) today announced that the list of shareholders on the homepage has been updated with information as of February 26, 2021. The 15 largest shareholders in InDex Pharmaceuticals Holding AB (publ) were as of February 26, 2021:                                     Publication The information was submitted for publication through the agency of the contact person set out above at 13:45 CET on March 12, 2021. InDex Pharmaceuticals in brief InDex is a pharmaceutical development company focusing on immunological diseases where there is a high unmet medical need for new treatment options. The Company s lead asset is the drug candidate cobitolimod, which is in late stage clinical development for the treatment of moderate to severe ulcerative colitis - a debilitating, chronic inflammatio

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.